The Latest Cardiac and Vascular News
Oxford University mathematics program paired students & faculty with Vironix technologists to develop and validate algorithms for synthetic patient data generation and detection of Congestive Heart Failure decompensation. AUSTIN, Texas, Aug. 9, 2022 /PRNewswire/ — Digital Health Company, Vironix Health, has teamed up with the Mathematical Modelling and Scientific Computing MSc, based within […]
US Based Pilot Study to enroll patients who develop communicating hydrocephalus following subarachnoid hemorrhage BOSTON, Aug. 9, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption […]
ST. LOUIS, Aug. 09, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022. “Despite macro pressures and the poor optics of our financial results, Stereotaxis is making significant progress […]
SANTA CLARA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2022. Recent Highlights Recognized revenue of $120.7 million […]
Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory Clearances in the United Kingdom and United States Anticipated in Second Half of 2022 Preclinical Data Supporting Nomination […]
Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of an anticipated Q4 2022 launch of FUROSCIX, if approved Ended Q2 with cash, cash equivalents, restricted cash and investments of $56.0 million […]
MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022, which included the following highlights: Generated $2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the first quarter of 2022, Enrolled first […]
– Generated 47.8% growth in CGuard™ revenue year-over-year – – Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission – – Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company – — Management to Host Investor Conference […]
REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational Science CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused […]
The Bodyport Cardiac Scale is available to monitor heart function and fluid status in a single step at home SAN FRANCISCO–(BUSINESS WIRE)–Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug […]
